{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T08:36:57Z","timestamp":1792571817690,"version":"4.5.0"},"reference-count":31,"publisher":"The Endocrine Society","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,9,1]]},"abstract":"<jats:p>Islet amyloid deposition in human type 2 diabetes results in \u03b2-cell loss. These amyloid deposits contain the unique amyloidogenic peptide human islet amyloid polypeptide (hIAPP), which is also a known substrate of the protease insulin-degrading enzyme (IDE). Whereas IDE inhibition has recently been demonstrated to improve glucose metabolism in mice, inhibiting it has also been shown to increase cell death when synthetic hIAPP is applied exogenously to a \u03b2-cell line. Thus, we wanted to determine whether a similar deleterious effect is observed when hIAPP is endogenously produced and secreted from islets. To address this issue, we cultured hIAPP transgenic mouse islets that have the propensity to form amyloid for 48 and 144 hours in 16.7 mM glucose in the presence and absence of the IDE inhibitor 1. At neither time interval did IDE inhibition increase amyloid formation or \u03b2-cell loss. Thus, the inhibition of IDE may represent an approach to improve glucose metabolism in human type 2 diabetes, without inducing amyloid deposition and its deleterious effects.<\/jats:p>","DOI":"10.1210\/en.2016-1410","type":"journal-article","created":{"date-parts":[[2016,7,12]],"date-time":"2016-07-12T19:07:12Z","timestamp":1468350432000},"page":"3462-3468","source":"Crossref","is-referenced-by-count":8,"title":["Inhibition of Insulin-Degrading Enzyme Does Not Increase Islet Amyloid Deposition in Vitro"],"prefix":"10.1210","volume":"157","author":[{"given":"Meghan F.","family":"Hogan","sequence":"first","affiliation":[{"name":"Division of Metabolism, Endocrinology, and Nutrition (M.F.H., D.T.M., S.Z., A.T.T., M.M., R.L.H., S.E.K.), Department of Medicine, Veterans Affairs Puget Sound Health Care System and University of Washington, Seattle, Washington 98108;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel T.","family":"Meier","sequence":"first","affiliation":[{"name":"Division of Metabolism, Endocrinology, and Nutrition (M.F.H., D.T.M., S.Z., A.T.T., M.M., R.L.H., S.E.K.), Department of Medicine, Veterans Affairs Puget Sound Health Care System and University of Washington, Seattle, Washington 98108;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakeneh","family":"Zraika","sequence":"first","affiliation":[{"name":"Division of Metabolism, Endocrinology, and Nutrition (M.F.H., D.T.M., S.Z., A.T.T., M.M., R.L.H., S.E.K.), Department of Medicine, Veterans Affairs Puget Sound Health Care System and University of Washington, Seattle, Washington 98108;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew T.","family":"Templin","sequence":"first","affiliation":[{"name":"Division of Metabolism, Endocrinology, and Nutrition (M.F.H., D.T.M., S.Z., A.T.T., M.M., R.L.H., S.E.K.), Department of Medicine, Veterans Affairs Puget Sound Health Care System and University of Washington, Seattle, Washington 98108;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahnaz","family":"Mellati","sequence":"first","affiliation":[{"name":"Division of Metabolism, Endocrinology, and Nutrition (M.F.H., D.T.M., S.Z., A.T.T., M.M., R.L.H., S.E.K.), Department of Medicine, Veterans Affairs Puget Sound Health Care System and University of Washington, Seattle, Washington 98108;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"Hull","sequence":"first","affiliation":[{"name":"Division of Metabolism, Endocrinology, and Nutrition (M.F.H., D.T.M., S.Z., A.T.T., M.M., R.L.H., S.E.K.), Department of Medicine, Veterans Affairs Puget Sound Health Care System and University of Washington, Seattle, Washington 98108;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm A.","family":"Leissring","sequence":"first","affiliation":[{"name":"Institute for Memory Impairments and Neurological Disorders (M.A.L.), University of California, Irvine, Irvine, California 92697"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E.","family":"Kahn","sequence":"first","affiliation":[{"name":"Division of Metabolism, Endocrinology, and Nutrition (M.F.H., D.T.M., S.Z., A.T.T., M.M., R.L.H., S.E.K.), Department of Medicine, Veterans Affairs Puget Sound Health Care System and University of Washington, Seattle, Washington 98108;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2016,6,12]]},"reference":[{"issue":"1","key":"2020071612484282200_B1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00125-002-1009-0","article-title":"The relative contributions of insulin resistance and \u03b2-cell dysfunction to the pathophysiology of type 2 diabetes","volume":"46","author":"Kahn","year":"2003","journal-title":"Diabetologia"},{"issue":"5","key":"2020071612484282200_B2","doi-asserted-by":"crossref","first-page":"e10504","DOI":"10.1371\/journal.pone.0010504","article-title":"Designed inhibitors of insulin-degrading enzyme regulate the catabolism and activity of insulin","volume":"5","author":"Leissring","year":"2010","journal-title":"PLoS One"},{"issue":"2","key":"2020071612484282200_B3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1517\/03009734000000014","article-title":"Quantitative studies of amyloid in the islets of Langerhans","volume":"77","author":"Westermark","year":"1972","journal-title":"Ups J Med Sci"},{"issue":"6","key":"2020071612484282200_B4","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1016\/j.ajpath.2011.02.036","article-title":"\u03b2-Cell loss and \u03b2-cell apoptosis in human type 2 diabetes are related to islet amyloid deposition","volume":"178","author":"Jurgens","year":"2011","journal-title":"Am J Pathol"},{"issue":"8","key":"2020071612484282200_B5","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1210\/jc.2004-0405","article-title":"Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes","volume":"89","author":"Hull","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2020071612484282200_B6","doi-asserted-by":"crossref","first-page":"634","DOI":"10.2337\/diab.39.5.634","article-title":"Evidence of cosecretion of islet amyloid polypeptide and insulin by \u03b2-cells","volume":"39","author":"Kahn","year":"1990","journal-title":"Diabetes"},{"key":"2020071612484282200_B7","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.2337\/diabetes.49.12.2056","article-title":"\u03b2-Cell glucokinase deficiency and hyperglycemia are associated with reduced islet amyloid deposition in a mouse model of type 2 diabetes","volume":"49","author":"Andrikopoulos","year":"2000","journal-title":"Diabetes"},{"issue":"7","key":"2020071612484282200_B8","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.2337\/diabetes.54.7.2235","article-title":"Long-term treatment with rosiglitazone and metformin reduces the extent of, but does not prevent, islet amyloid deposition in mice expressing the gene for human islet amyloid polypeptide","volume":"54","author":"Hull","year":"2005","journal-title":"Diabetes"},{"issue":"4","key":"2020071612484282200_B9","doi-asserted-by":"crossref","first-page":"E475","DOI":"10.1152\/ajpendo.00025.2013","article-title":"One year of sitagliptin treatment protects against islet amyloid-associated \u03b2-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice","volume":"305","author":"Aston-Mourney","year":"2013","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"7","key":"2020071612484282200_B10","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1007\/s00125-011-2143-3","article-title":"Exendin-4 increases islet amyloid deposition but offsets the resultant \u03b2 cell toxicity in human islet amyloid polypeptide transgenic mouse islets","volume":"54","author":"Aston-Mourney","year":"2011","journal-title":"Diabetologia"},{"issue":"47","key":"2020071612484282200_B11","doi-asserted-by":"crossref","first-page":"36621","DOI":"10.1074\/jbc.M006170200","article-title":"Degradation of amylin by insulin-degrading enzyme","volume":"275","author":"Bennett","year":"2000","journal-title":"J Biol Chem"},{"issue":"9","key":"2020071612484282200_B12","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.2337\/diabetes.52.9.2315","article-title":"An insulin-degrading enzyme inhibitor decreases amylin degradation, increases amylin-induced cytotoxicity, and increases amyloid formation in insulinoma cell cultures","volume":"52","author":"Bennett","year":"2003","journal-title":"Diabetes"},{"issue":"7507","key":"2020071612484282200_B13","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/nature13297","article-title":"Anti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormones","volume":"511","author":"Maianti","year":"2014","journal-title":"Nature"},{"issue":"13","key":"2020071612484282200_B14","doi-asserted-by":"crossref","first-page":"5036","DOI":"10.1073\/pnas.87.13.5036","article-title":"Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation","volume":"87","author":"Westermark","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"2020071612484282200_B15","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.2337\/diab.43.12.1457","article-title":"Pancreatic expression and secretion of human islet amyloid polypeptide in a transgenic mouse","volume":"43","author":"D'Alessio","year":"1994","journal-title":"Diabetes"},{"issue":"1","key":"2020071612484282200_B16","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.bbrc.2006.12.187","article-title":"Glucose- and time-dependence of islet amyloid formation in vitro","volume":"354","author":"Zraika","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"issue":"8","key":"2020071612484282200_B17","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1369\/0022155415585995","article-title":"Determination of optimal sample size for quantification of \u03b2-cell area, amyloid area and \u03b2-cell apoptosis in isolated islets","volume":"63","author":"Meier","year":"2015","journal-title":"J Histochem Cytochem"},{"issue":"7","key":"2020071612484282200_B18","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/BF00417699","article-title":"Transgenic mice overproducing islet amyloid polypeptide have increased insulin storage and secretion in vitro","volume":"37","author":"Verchere","year":"1994","journal-title":"Diabetologia"},{"issue":"4","key":"2020071612484282200_B19","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1007\/s00125-008-1255-x","article-title":"Oxidative stress is induced by islet amyloid formation and time-dependently mediates amyloid-induced \u03b2 cell apoptosis","volume":"52","author":"Zraika","year":"2009","journal-title":"Diabetologia"},{"issue":"39","key":"2020071612484282200_B20","doi-asserted-by":"crossref","first-page":"37314","DOI":"10.1074\/jbc.M305627200","article-title":"Kinetics of amyloid \u03b2-protein degradation determined by novel fluorescence- and fluorescence polarization-based assays","volume":"278","author":"Leissring","year":"2003","journal-title":"J Biol Chem"},{"issue":"5","key":"2020071612484282200_B21","first-page":"608","article-title":"Insulin degradation: progress and potential","volume":"19","author":"Duckworth","year":"1998","journal-title":"Endocr Rev"},{"issue":"24","key":"2020071612484282200_B22","doi-asserted-by":"crossref","first-page":"18177","DOI":"10.1074\/jbc.M109.082032","article-title":"Neprilysin impedes islet amyloid formation by inhibition of fibril formation rather than peptide degradation","volume":"285","author":"Zraika","year":"2010","journal-title":"J Biol Chem"},{"issue":"5","key":"2020071612484282200_B23","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1074\/jbc.M112.438457","article-title":"Matrix metalloproteinase-9 reduces islet amyloid formation by degrading islet amyloid polypeptide","volume":"288","author":"Aston-Mourney","year":"2013","journal-title":"J Biol Chem"},{"issue":"12","key":"2020071612484282200_B24","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1021\/acschembio.5b00334","article-title":"Selective targeting of extracellular insulin-degrading enzyme by quasi-irreversible thiol-modifying inhibitors","volume":"10","author":"Abdul-Hay","year":"2015","journal-title":"ACS Chem Biol"},{"issue":"18","key":"2020071612484282200_B25","doi-asserted-by":"crossref","first-page":"8467","DOI":"10.1073\/pnas.91.18.8467","article-title":"Intra- and extracellular amyloid fibrils are formed in cultured pancreatic islets of transgenic mice expressing human islet amyloid polypeptide","volume":"91","author":"de Koning","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"2020071612484282200_B26","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1073\/pnas.93.8.3492","article-title":"Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic \u03b2 cell expression of human islet amyloid polypeptide","volume":"93","author":"Verchere","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"2020071612484282200_B27","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0925-4439(01)00078-3","article-title":"Islet amyloid and type 2 diabetes: from molecular misfolding to islet pathophysiology","volume":"1537","author":"Jaikaran","year":"2001","journal-title":"Biochim Biophys Acta"},{"issue":"10","key":"2020071612484282200_B28","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s001250051295","article-title":"Amyloid fibril formation is progressive and correlates with \u03b2-cell secretion in transgenic mouse isolated islets","volume":"42","author":"MacArthur","year":"1999","journal-title":"Diabetologia"},{"issue":"4","key":"2020071612484282200_B29","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/0196-9781(92)90181-2","article-title":"Identification of neuropeptide-degrading enzymes in the pancreas","volume":"13","author":"Terashima","year":"1992","journal-title":"Peptides"},{"issue":"1","key":"2020071612484282200_B30","first-page":"47","article-title":"Gelatinases and inhibitors of gelatinases in pancreatic islets and islet cell tumors","volume":"10","author":"Tomita","year":"1997","journal-title":"Mod. Pathol"},{"issue":"4","key":"2020071612484282200_B31","doi-asserted-by":"crossref","first-page":"640","DOI":"10.2337\/diabetes.47.4.640","article-title":"Reduced amylin release is a characteristic of impaired glucose tolerance and type 2 diabetes in Japanese Americans","volume":"47","author":"Kahn","year":"1998","journal-title":"Diabetes"}],"container-title":["Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/endo\/article-pdf\/157\/9\/3462\/10829034\/endo3462.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/endo\/article-pdf\/157\/9\/3462\/10829034\/endo3462.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T21:58:55Z","timestamp":1594936735000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/endo\/article\/157\/9\/3462\/2422398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,12]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9,1]]}},"URL":"https:\/\/doi.org\/10.1210\/en.2016-1410","relation":{},"ISSN":["0013-7227","1945-7170"],"issn-type":[{"value":"0013-7227","type":"print"},{"value":"1945-7170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,12]]}}}